Azu­ri­ty Phar­ma­ceu­ti­cals con­tin­ues its win streak as it bags an­oth­er ap­proval from the FDA

Mass­a­chu­setts-based Azu­ri­ty Phar­ma­ceu­ti­cals has been do­ing well this year in get­ting its prod­ucts past FDA ap­proval, and the com­pa­ny is look­ing to con­tin­ue that trend Fri­day.

Ac­cord­ing to the pri­vate­ly held com­pa­ny, the FDA ap­proved its lat­est treat­ment, Kon­vomep, de­signed to treat gas­tric ul­cers as well as re­duce the risk of up­per gas­troin­testi­nal bleed­ing in adults. The treat­ment it­self is a com­bi­na­tion of omepra­zole, a pro­ton pump in­hibitor, and sodi­um bi­car­bon­ate. So far, reg­u­la­tors have on­ly ap­proved it for adults, as the ef­fec­tive­ness in pe­di­atric pa­tients has not been es­tab­lished.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER